Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Li-Jen Cheng, Grace Wong, Wen-Yee Chay, Joanne Ngeow, Yongqiang Tan, Swee Sung Soon, Mohamed Ismail Abdul Aziz, Fiona Pearce & Kwong Ng. (2021) Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 441-448.
Read now
Read now
Chia-Sui Weng, Chao-Chih Wu, Tze-Chien Chen, Jen-Ruei Chen, Chueh-Yi Huang & Chih-Long Chang. (2019) Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin. Cancer Management and Research 11, pages 9899-9905.
Read now
Read now
Joanna Moes-Sosnowska, Iwona K. Rzepecka, Joanna Chodzynska, Agnieszka Dansonka-Mieszkowska, Lukasz M. Szafron, Aneta Balabas, Renata Lotocka, Piotr Sobiczewski & Jolanta Kupryjanczyk. (2019) Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas. Cancer Biology & Therapy 20:6, pages 843-854.
Read now
Read now
Articles from other publishers (30)
Matteo Bruno, Manuela Ludovisi, Carlo Ronsini, Giulia Capanna, Guglielmo Stabile & Maurizio Guido. (2023) Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR. Medicina 59:3, pages 606.
Crossref
Crossref
Qian Zhao, Jing Ni, Jiayin Dong, Xianzhong Cheng, Li Xiao, Qi Xue, Xia Xu, Wenwen Guo & Xiaoxiang Chen. (2022) Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report. Reproductive Sciences 30:2, pages 615-621.
Crossref
Crossref
Andrey Kechin, Ulyana Boyarskikh, Alexey Barinov, Alexander Tanas, Svetlana Kazakova, Anastasia Zhevlova, Evgeniy Khrapov, Sergey Subbotin, Olga Mishukova, Tatiana Kekeeva, Irina Demidova & Maxim Filipenko. (2022) A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. Breast Cancer Research and Treatment 197:2, pages 387-395.
Crossref
Crossref
Kh. B. Kotiv, T. V. Gorodnova, A. P. Sokolenko, I. V. Berlev & E. N. Imyanitov. (2022) Hereditary ovarian cancer. Siberian journal of oncology 21:5, pages 123-134.
Crossref
Crossref
Antonio González-Martín, Ursula A Matulonis, Jacob Korach, Mansoor R Mirza, Kathleen N Moore, Xiaohua WuWhitney York, Divya Gupta, Stanislav Lechpammer & Bradley J Monk. (2022)
Niraparib treatment for patients with
BRCA
-mutated ovarian cancer: review of clinical data and therapeutic context
. Future Oncology 18:23, pages 2505-2536.
Crossref
Crossref
Annamaria Ferrero, Martina Borghese, Stefano Restaino, Andrea Puppo, Giuseppe Vizzielli & Nicoletta Biglia. (2022) Predicting Response to Anthracyclines in Ovarian Cancer. International Journal of Environmental Research and Public Health 19:7, pages 4260.
Crossref
Crossref
Maria Russi, Domenico Marson, Alice Fermeglia, Suzana Aulic, Maurizio Fermeglia, Erik Laurini & Sabrina Pricl. (2022) The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer. Pharmacology & Therapeutics 232, pages 108009.
Crossref
Crossref
Caterina Fumagalli, Ilaria Betella, Alessandra Rappa, Maria di Giminiani, Michela Gaiano, Luigi Antonio De Vitis, Benedetta Zambetti, Davide Vacirca, Francesco Multinu, Konstantinos Venetis, Nicoletta Colombo, Massimo Barberis & Elena Guerini Rocco. (2022) Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients. Cancers 14:7, pages 1638.
Crossref
Crossref
Cynthia Villarreal-Garza, Ana S. Ferrigno, Alejandro Aranda-Gutierrez, Paul H. Frankel, Nora H. Ruel, Alan Fonseca, Steven Narod, Yanin Chavarri-Guerra, Erika Sifuentes, Maria Cristina Magallanes-Hoyos, Josef Herzog, Danielle Castillo, Rosa M. Alvarez-Gomez, Alejandro Mohar-Betancourt & Jeffrey N. Weitzel. (2021)
Influence of Germline
BRCA
Genotype on the Survival of Patients with Triple-Negative Breast Cancer
. Cancer Research Communications 1:3, pages 140-147.
Crossref
Crossref
Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, Felipe Leonardo Estati, Adriana Regina Gonçalves Ribeiro, Daniella Yumi Tsuji Honda, Mariana de Oliveira, Joao Paulo da Silveira Nogueira Lima, Elizabeth Santana dos Santos, Andrea Paiva Gadelha Guimarães, Glauco Baiocchi & Alexandre André Balieiro Anastácio da Costa. (2021) Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort. BMC Cancer 21:1.
Crossref
Crossref
Cécile Le Page, Setor Amuzu, Kurosh Rahimi, Walter Gotlieb, Jiannis Ragoussis & Patricia N. Tonin. (2021) Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers. Seminars in Cancer Biology 77, pages 110-126.
Crossref
Crossref
Ximu Sun, Xin Wang, Jie Zhang, Zhixia Zhao, Xin Feng, Lihong Liu & Zhuo Ma. (2021) Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. The Breast 60, pages 26-34.
Crossref
Crossref
Ning Ren, Leyin Zhang, Jieru Yu, Siqi Guan, Xinyang Dai, Leitao Sun & Minli Ying. (2021) Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology 11.
Crossref
Crossref
L. Tobalina, J. Armenia, E. Irving, M.J. O'Connor & J.V. Forment. (2021) A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Annals of Oncology 32:1, pages 103-112.
Crossref
Crossref
John J. Krais & Neil Johnson. (2020) BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. Cancer Research 80:21, pages 4601-4609.
Crossref
Crossref
Roshni D. Kalachand, Ciaran O’Riain, Sinead Toomey, Aoife Carr, Kirsten M. Timms, Sharon O’Toole, Stephen Madden, Mark Bates, John J. O’Leary, Noreen Gleeson, Dearbhaile O’Donnell, Liam Grogan, Oscar Breathnach, Angela Farrelly, Britta Stordal & Bryan T. Hennessy. (2020) Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstetrics & Gynecology Science 63:5, pages 643-654.
Crossref
Crossref
Kelli Swan, Kali Chatham Dougherty & Sara Wienke Myers. (2020) Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. Current Genetic Medicine Reports 8:3, pages 109-119.
Crossref
Crossref
Yifan Jiang, Juan Zhao, Li Zhang, Sijuan Tian, Ting Yang, Li Wang, Minyi Zhao, Qing Yang, Yaohui Wang & Xiaofeng Yang. (2020) Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. Frontiers in Oncology 10.
Crossref
Crossref
V Gallotta, M Bruno, C Conte, MT Giudice, F Davià, F Moro, GF Zannoni, A Fagotti, M De Bonis, E Capoluongo, G Scambia & G Ferrandina. (2020) Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status. European Journal of Surgical Oncology 46:7, pages 1327-1333.
Crossref
Crossref
Ieva Sadzevičienė, Olga Liaugaudienė, Justinas Besusparis, Jolita Asadauskienė, Ilona Kulikienė, Birutė Brasiūnienė, Rasa Sabaliauskaitė & Sonata Jarmalaitė. (2020) Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family. Medicina 56:3, pages 119.
Crossref
Crossref
Guang‐Cai Li, Xu‐Ling Qin, Huai‐Hua Song, Ying‐Ni Li, Yu‐Yan Qiu, Shi‐Chang Cui, Yong‐Sheng Wang, Hui Wang & Jun‐Ling Gong. (2019)
Retracted
: Upregulated microRNA‐15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3
. Journal of Cellular Physiology 234:12, pages 22331-22342.
Crossref
Crossref
Valerio Gallotta, Carmine Conte, Marco D’Indinosante, Ettore Capoluongo, Angelo Minucci, Agostino Maria De Rose, Francesco Ardito, Felice Giuliante, Andrea Di Giorgio, Gian Franco Zannoni, Anna Fagotti, Christian Margreiter, Giovanni Scambia & Gabriella Ferrandina. (2019) Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases. European Journal of Surgical Oncology 45:11, pages 2096-2102.
Crossref
Crossref
Federica Tomao, Erlisa Bardhi, Anna Di Pinto, Carolina Maria Sassu, Elena Biagioli, Maria Cristina Petrella, Innocenza Palaia, Ludovico Muzii, Nicoletta Colombo & Pierluigi Benedetti Panici. (2019) Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treatment Reviews 80, pages 101909.
Crossref
Crossref
Yehuda G. Assaraf, Anamaria Brozovic, Ana Cristina Gonçalves, Dana Jurkovicova, Aija Linē, Miguel Machuqueiro, Simona Saponara, Ana Bela Sarmento-Ribeiro, Cristina P.R. Xavier & M. Helena Vasconcelos. (2019) The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 46, pages 100645.
Crossref
Crossref
Paul A. Cohen, Aime Powell, Steffen Böhm, C. Blake Gilks, Colin J.R. Stewart, Tarek M. Meniawy, Max Bulsara, Stefanie Avril, Eleanor C. Brockbank, Tjalling Bosse, Gustavo Rubino de Azevedo Focchi, Raji Ganesan, Rosalind M. Glasspool, Brooke E. Howitt, Hyun-Soo Kim, Jung-Yun Lee, Nhu D. Le, Michelle Lockley, Ranjit Manchanda, Trupti Mandalia, W. Glenn McCluggage, Iain McNeish, Divya Midha, Radhika Srinivasan, Yun Yi Tan, Rachael van der Griend, Mayu Yunokawa, Gian F. Zannoni, Naveena Singh, Simi Aggarwal, Holger Bronger, Elizabeth B. Brown, Martin Buck, Syed A. Bukhari, Edwina Coghlan, Nichola Cope, Michelle Samora de Almeida, Cornelius D. De Kroon, Andrew Dean, Michael-John Devlin, Helena M. Ditzel, Enken Drecoll, Takahiro Ebata, Anna Fagotti, Asma Faruqi, Laura Feeney, Kavita Gupta, Ian Harley, Frediano Inzani, Arjun R. Jeyarajah, M.H. Eleanor Koay, Judith R. Kroep, Jung-Yun Lee, Yee Leung, Michelle Lockley, Alice R. Loft, Daniel MaGee, Ranjit Manchanda, Sarah McKenna, Divya Midha, David Millan, Joanne Millar, Rowan Miller, Ganendra R. Mohan, Sohail Mughal, Asima Mukhopadhyay, Sergio Mancini Nicolau, James Nevin, Abigail S. Oakley, Mary Quigley, Bhavana Rai, Arvind Rajwanshi, Stuart G. Salfinger, Giovanni Scambia, Kate Scatchard, Barbara Schmalfeldt, Bryony Simcock, Priya Singh, Kyle C. Strickland, Vainta Suri, Sheeba Syed, Peter Sykes, Kenji Tamura, Adeline Tan, Jason Tan, Emily Thompson, Anna V. Tinker, Georgia Trevisan, Maria Gabriela Baumgarten Kuster Uyeda, Michelle M. Vaughan, Wilko Weichert, Anthony Williams, Sarah Williams, Hiroshi Yoshida & Pier Carlo Zorzato. (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology 154:2, pages 441-448.
Crossref
Crossref
Aoife J McCarthy, Marjan Rouzbahman, Sakinah A Thiryayi, William B Chapman & Blaise A Clarke. (2019) Neoadjuvant therapy in gynaecological malignancies: What pathologists need to know. Journal of Clinical Pathology 72:2, pages 102-111.
Crossref
Crossref
Gwen Lomberk & Raul Urrutia. 2019. Management of Localized Pancreatic Cancer. Management of Localized Pancreatic Cancer
187
198
.
Qilian Yang, Yuqing Yang, Nianxin Zhou, Kexin Tang, Wayne Bond Lau, Bonnie Lau, Wei Wang, Lian Xu, Zhengnan Yang, Shuang Huang, Xin Wang, Tao Yi, Xia Zhao, Yuquan Wei, Hongjing Wang, Linjie Zhao & Shengtao Zhou. (2018) Epigenetics in ovarian cancer: premise, properties, and perspectives. Molecular Cancer 17:1.
Crossref
Crossref
Amy K. Wagner. (2017) TBI Rehabilomics Research: an Exemplar of a Biomarker-Based Approach to Precision Care for Populations with Disability. Current Neurology and Neuroscience Reports 17:11.
Crossref
Crossref
Lilian Van Wagensveld, Olivier Colomban, Maaike van der Aa, Gilles Freyer, Hugo M. Horlings, Gabe Sonke, Roy Kruitwagen & Benoit You. (2021) The Prognostic Value of the CA-125 Elimination Rate (KELIM) as an Indicator of Response During Neo-Adjuvant Chemotherapy in Advanced-Stage Ovarian Cancer. SSRN Electronic Journal.
Crossref
Crossref